Novel Therapies in the Management of Advanced Renal
Cell Carcinoma (RCC): New Strategies and Options

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Exelixis, Inc and Novartis Pharmaceuticals

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Almost all patients with advanced renal cell cancer are incurable. Fortunately for patients with advanced RCC, several new treatments, including immunotherapies and targeted therapies, have recently become available giving clinicians new options to improve patient outcomes and quality of life. This activity will focus on these evolving options, how to integrate them into the treatment paradigm, options for patients who have received prior therapies, and how to apply evidence-based data to select appropriate treatment regimens and manage toxicities

Upon Completion of this activity, participants will be able to:

  • Review the characteristics and mechanism of action of different targeted agents and immunotherapies for advanced renal cell carcinoma (RCC)

  • Analyze emerging mechanistic approaches to overcome anti-angiogenic resistant advanced RCC

  • Integrate the latest therapies into practice in a timely, evidence-based, and patient-centric manner as part of the management of previously treated patients with advanced RCC

  • Examine the role of tyrosine kinase inhibitors (TKIs) in the management of patients with advanced RCC

  • Apply knowledge concerning adverse-event profiles to consider their impact on clinical decision making to individualize sequencing and manage predictable treatment-related toxicities linked to treatments for advanced RCC

Faculty: M. Dror Michaelson, MD, PhD
Associate Professor of Medicine
Clinical Director, Urologic Oncology
Massachusetts General Hospital Cancer Center


Dr. Michaelson serves on advisory board/panel for Exelixis, Novartis and Pfizer. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Exelixis, Inc and Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue